Zoledronic Acid Prevents Bone Loss during Endocrine Therapy
 

SAN ANTONIO, Dec. 14 -- Premenopausal breast cancer patients receiving adjuvant endocrine therapy did not suffer the substantial bone loss typically seen with such treatment when they were also given zoledronic acid (Zometa), updated results from a randomized clinical trial showed

To read full article: http://www.medpagetoday.com/MeetingC...eeting/tb/7690